Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab vedotin + pyrotinib vs THP in HER2+ advanced breast cancer
NCT06278870Phase 3Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2023
- Primary completion
- Jun 2031
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of disitamab vedotin and pyrotinib in HER2-positive metastatic breast cancer (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Progression Free Survival at 30 months. Started Sep 2023; status: recruiting.
02
Drugs
disitamab vedotinpyrotinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT06278870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06278870.